ci-1040
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2002 (NCT00034827)
Timeline
2000s
- Jan 1, 2002
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
MAP2K2 inhibitor
Allosteric inhibitor
MAP2K1 inhibitor
Allosteric inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
O=C(NOCC1CC1)c1ccc(F)c(F)c1Nc1ccc(I)cc1Cl- Mol. weight
- 478.66 g/mol
- Lipinski Ro5
- 1 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL105442 ↗
Also known as
- 2-(2-chloro-4-iodophenylamino)-n-cyclopropylmethoxy-3,4-difluorobenzamide
- ci 1040
- ci-1040
- ci-1040
- ci-1040
- ci-1040
- ci-1040
- pd-18435
- pd-18435
- pd184352
- pd 184352
- pd-184352
- pd-184352
- pd-184352
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00033384 | Phase 2 | Feb 1, 2002 | National Cancer Institute (NCI), University of Alabama, Birmingham |
| NCT00034827 | Phase 2 | Jan 1, 2002 | Pfizer |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2002 |
| Pfizer | For profit | 1 | 1 | 1 | 2002 |
| University of Alabama, Birmingham | Academic/Hospital | 1 | 1 | 1 | 2002 |
3 organizations
Page 1 / 1